Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Apple Turns 50: From Garage Startup to AI Crossroads 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
SK bioscience, a South Korean pharmaceutical firm, announced on Thursday, March 21, that it has exported its influenza vaccine to Thailand. The company developed a cell-cultured influenza vaccine, and after securing the required approvals and permits, it started exporting its Sky Cellflu to the country.
First Batch of Deliveries
According to The Korea Herald, SK Bioscience has already completed the first delivery, which consists of 440,000 doses of the Sky Cellflu vaccine. The products were handed over to its local partner, Biogenetech.
The Korean pharmaceutical company expects to receive more orders and expand its sales once the new influenza vaccine is distributed in Thailand. The deal also marks SK Bioscience's expansion in the Southeast Asian market and entry into the Southern space.
Timely Arrival of the Flu Vaccines
Korea IT Times reported that Thailand has been affected by flu strains, and vaccination is being sought to prevent infections. SK bioscience's Sky Cellflu was also approved by the World Health Organization (WHO) for use in the country.
Moreover, this export is expected to become an excellent example of proper vaccination to combat influenza. Meanwhile, Sky Cellflu already secured proper licenses for distribution in 12 countries, including Malaysia, Thailand, Chile, Singapore, Mongolia, and Pakistan.
World's First Cell Culture-Based Flu Vaccine
SK bioscience's SKYCellflu is said to be the first cell culture-based influenza vaccine in the world. It obtained WHO Pre-qualification (PQ) certification for safe usage and dissemination worldwide.
"The export of SKYCellflu to Thailand serves as a stepping-stone for entering the Southeast Asian and Southern Hemisphere markets and expanding into the global market," SK bioscience's chief executive officer, Ahn Jae Yong, said in a press release. "In addition to diversifying our existing product markets, we are committed to developing vaccines with blockbuster potential, such as our next-generation pneumococcal conjugate vaccine candidate, which is expected to enter phase III clinical trials this year."
Photo by: SK Bioscience Press Release
